Since both EGF and CSN6 signaling pathways can promote FASN accumulation, it is reasonable to deduce that inhibiting EGF signaling by cetuximab treatment plus attenuating FASN activity by orlistat might synergistically suppress CSN6-high CRC growth. The gene discussed is COPS6; the disease is colorectal carcinoma.